Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL684795 | 1.00 | L3MBTL1 (0.35) | L3MBTL1GAANPSR1CNR2POLB | |
| SCHEMBL24263338 | 0.84 | L3MBTL1 (0.37) | L3MBTL1GAANPSR1CNR2POLB | |
| SCHEMBL22600649 | 0.84 | L3MBTL1 (0.37) | L3MBTL1GAANPSR1CNR2POLB | |
| SCHEMBL20021568 | 0.83 | RIPK1 (0.40) | POLB | |
| SCHEMBL17373358 | 0.83 | CA2 (0.39) | L3MBTL1NPSR1CNR2POLBMAPK1 | |
| SCHEMBL28433567 | 0.83 | CA2 (0.39) | L3MBTL1NPSR1CNR2POLBMAPK1 | |
| SCHEMBL17373361 | 0.83 | CA2 (0.39) | L3MBTL1NPSR1CNR2POLBMAPK1 | |
| SCHEMBL17432119 | 0.83 | GAA (0.33) | L3MBTL1GAANPSR1CNR2POLB | |
| SCHEMBL13543178 | 0.83 | ADAM17 (0.33) | ALDH1A1 | |
| SCHEMBL19849496 | 0.81 | MME (0.30) | L3MBTL1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-20200207730-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-07-02 | — | — | US | disclosed |
| US-20190076405-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASASIS OF CANCER CELLS | EyePoint Pharmaceuticals, Inc. | 2019-03-14 | — | — | US | disclosed |
| US-9949956-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180092883-A1 | PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-04-05 | — | — | US | disclosed |
| US-20180092883-A1 | PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-04-05 | — | — | US | disclosed |
| US-20180037579-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-20180037579-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-20180022741-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-01-25 | — | — | US | disclosed |
| US-20180022741-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-01-25 | — | — | US | disclosed |
| US-20140288134-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | AERPIO THERAPEUTICS INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140275103-A1 | Compositions, formulations and methods for treating ocular diseases | AERPIO THERAPEUTICS INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140249100-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | AERPIO THERAPEUTICS INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140242026-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EyePoint, Inc. | 2014-08-28 | — | — | US | disclosed |
| US-20140179693-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | SHALWITZ ROBERT (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140066458-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2014-03-06 | — | — | US | disclosed |
| US-8569348-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2012-05-24 | — | — | US | disclosed |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EyePoint, Inc. | 2012-05-24 | — | — | US | disclosed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | L3MBTL1 3091/4885GAA 2854/4885NPSR1 4414/4885 |
| US-20140242026-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | L3MBTL1 1016/4885GAA 2801/4885NPSR1 3550/4885 |
| US-20140066458-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | L3MBTL1 1026/4885GAA 2308/4885NPSR1 1187/4885 |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | L3MBTL1 1016/4885GAA 2801/4885NPSR1 3550/4885 |
| US-20200207730-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | L3MBTL1 1026/4885GAA 2308/4885NPSR1 1187/4885 |
| US-20140288134-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | L3MBTL1 3091/4885GAA 2854/4885NPSR1 4414/4885 |
| US-20140275103-A1 | Compositions, formulations and methods for treating ocular diseases | TIE1, TEK, KDR | L3MBTL1 4715/4885GAA 2788/4885NPSR1 3353/4885 |
| US-20140249100-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | L3MBTL1 1016/4885GAA 2801/4885NPSR1 3550/4885 |
| US-20190076405-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASASIS OF CANCER CELLS | TSG101, MMP8, EPCAM | L3MBTL1 1739/4885GAA 1591/4885NPSR1 2466/4885 |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | L3MBTL1 1026/4885GAA 2308/4885NPSR1 1187/4885 |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | L3MBTL1 1026/4885GAA 2308/4885NPSR1 1187/4885 |
| US-20140179693-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, EPCAM | L3MBTL1 763/4885GAA 2139/4885NPSR1 2892/4885 |
| US-20180037579-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | L3MBTL1 3091/4885GAA 2854/4885NPSR1 4414/4885 |
| US-20180022741-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | L3MBTL1 4715/4885GAA 2788/4885NPSR1 3353/4885 |
| US-20180092883-A1 | PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES | PPM1G, PPM1F, PPM1A | L3MBTL1 4731/4885GAA 673/4885NPSR1 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.